|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TENT5A |
Gene summary for TENT5A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TENT5A | Gene ID | 55603 |
| Gene name | terminal nucleotidyltransferase 5A | |
| Gene Alias | C6orf37 | |
| Cytomap | 6q14.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96IP4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55603 | TENT5A | LZE7T | Human | Esophagus | ESCC | 6.33e-03 | 1.95e-01 | 0.0667 |
| 55603 | TENT5A | LZE8T | Human | Esophagus | ESCC | 2.53e-15 | 5.59e-01 | 0.067 |
| 55603 | TENT5A | LZE20T | Human | Esophagus | ESCC | 1.28e-30 | 1.15e+00 | 0.0662 |
| 55603 | TENT5A | LZE22T | Human | Esophagus | ESCC | 1.54e-04 | 4.90e-01 | 0.068 |
| 55603 | TENT5A | LZE24T | Human | Esophagus | ESCC | 5.01e-24 | 7.46e-01 | 0.0596 |
| 55603 | TENT5A | LZE22D3 | Human | Esophagus | HGIN | 1.28e-05 | 6.52e-01 | 0.0653 |
| 55603 | TENT5A | LZE6T | Human | Esophagus | ESCC | 9.07e-08 | 4.91e-01 | 0.0845 |
| 55603 | TENT5A | NAFLD1 | Human | Liver | NAFLD | 6.54e-09 | 7.77e-01 | -0.04 |
| 55603 | TENT5A | HCC1_Meng | Human | Liver | HCC | 4.33e-03 | -1.30e-01 | 0.0246 |
| 55603 | TENT5A | cirrhotic1 | Human | Liver | Cirrhotic | 9.14e-03 | -1.30e-01 | 0.0202 |
| 55603 | TENT5A | cirrhotic2 | Human | Liver | Cirrhotic | 4.33e-03 | -1.30e-01 | 0.0201 |
| 55603 | TENT5A | Pt13.a | Human | Liver | HCC | 4.33e-03 | -1.30e-01 | 0.021 |
| 55603 | TENT5A | Pt14.d | Human | Liver | HCC | 4.33e-03 | -1.30e-01 | 0.0143 |
| 55603 | TENT5A | S014 | Human | Liver | HCC | 2.08e-09 | 5.82e-01 | 0.2254 |
| 55603 | TENT5A | S015 | Human | Liver | HCC | 7.06e-07 | 4.59e-01 | 0.2375 |
| 55603 | TENT5A | S016 | Human | Liver | HCC | 1.23e-03 | 2.55e-01 | 0.2243 |
| 55603 | TENT5A | S027 | Human | Liver | HCC | 3.43e-09 | 9.46e-01 | 0.2446 |
| 55603 | TENT5A | S028 | Human | Liver | HCC | 1.76e-18 | 8.94e-01 | 0.2503 |
| 55603 | TENT5A | S029 | Human | Liver | HCC | 5.76e-17 | 1.11e+00 | 0.2581 |
| 55603 | TENT5A | TD9 | Human | Lung | IAC | 8.30e-17 | 1.42e+00 | 0.088 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00098957 | Liver | NAFLD | negative regulation of catabolic process | 65/1882 | 320/18723 | 2.50e-08 | 2.71e-06 | 65 |
| GO:00434886 | Liver | NAFLD | regulation of mRNA stability | 39/1882 | 158/18723 | 8.49e-08 | 7.09e-06 | 39 |
| GO:00313307 | Liver | NAFLD | negative regulation of cellular catabolic process | 55/1882 | 262/18723 | 9.35e-08 | 7.59e-06 | 55 |
| GO:00434876 | Liver | NAFLD | regulation of RNA stability | 40/1882 | 170/18723 | 2.32e-07 | 1.58e-05 | 40 |
| GO:19033127 | Liver | NAFLD | negative regulation of mRNA metabolic process | 21/1882 | 92/18723 | 2.56e-04 | 4.17e-03 | 21 |
| GO:19023695 | Liver | NAFLD | negative regulation of RNA catabolic process | 18/1882 | 75/18723 | 3.60e-04 | 5.42e-03 | 18 |
| GO:19023735 | Liver | NAFLD | negative regulation of mRNA catabolic process | 15/1882 | 63/18723 | 1.18e-03 | 1.36e-02 | 15 |
| GO:00434895 | Liver | NAFLD | RNA stabilization | 15/1882 | 65/18723 | 1.66e-03 | 1.74e-02 | 15 |
| GO:00482556 | Liver | NAFLD | mRNA stabilization | 13/1882 | 56/18723 | 3.12e-03 | 2.79e-02 | 13 |
| GO:190136111 | Liver | Cirrhotic | organic cyclic compound catabolic process | 213/4634 | 495/18723 | 1.58e-19 | 3.67e-17 | 213 |
| GO:001943911 | Liver | Cirrhotic | aromatic compound catabolic process | 202/4634 | 467/18723 | 6.93e-19 | 1.28e-16 | 202 |
| GO:190331111 | Liver | Cirrhotic | regulation of mRNA metabolic process | 140/4634 | 288/18723 | 1.07e-18 | 1.91e-16 | 140 |
| GO:004427011 | Liver | Cirrhotic | cellular nitrogen compound catabolic process | 195/4634 | 451/18723 | 2.99e-18 | 4.94e-16 | 195 |
| GO:004670011 | Liver | Cirrhotic | heterocycle catabolic process | 192/4634 | 445/18723 | 7.17e-18 | 1.12e-15 | 192 |
| GO:003465511 | Liver | Cirrhotic | nucleobase-containing compound catabolic process | 171/4634 | 407/18723 | 9.07e-15 | 9.33e-13 | 171 |
| GO:000640111 | Liver | Cirrhotic | RNA catabolic process | 126/4634 | 278/18723 | 4.64e-14 | 4.10e-12 | 126 |
| GO:000640211 | Liver | Cirrhotic | mRNA catabolic process | 109/4634 | 232/18723 | 1.30e-13 | 1.09e-11 | 109 |
| GO:000989512 | Liver | Cirrhotic | negative regulation of catabolic process | 121/4634 | 320/18723 | 1.21e-07 | 3.39e-06 | 121 |
| GO:004348811 | Liver | Cirrhotic | regulation of mRNA stability | 69/4634 | 158/18723 | 1.44e-07 | 3.87e-06 | 69 |
| GO:004348711 | Liver | Cirrhotic | regulation of RNA stability | 73/4634 | 170/18723 | 1.44e-07 | 3.87e-06 | 73 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |